Evolution of priorities in strategic funding for collaborative health research.

A comparison of the European Union Framework Programmes to the program funding by the United States National Institutes of Health

David Fajardo-Ortiz^{1*}, Bart Thijs², Wolfgang Glänzel², Karin R. Sipido^{1*}

1. Department of Cardiovascular Sciences, KU Leuven, Leuven. Belgium

2. Department of Management, Strategy and Innovation, Faculty of Economics and Business, KU Leuven, Leuven, Belgium

* Corresponding Authors

David.Fajardo@kuleuven.be, davguifaj@gmail.com; Karin.Sipido@kuleuven.be

Address for correspondence: Division of Experimental Cardiology Department of Cardiovascular Sciences KU Leuven Campus Gasthuisberg Herestraat 49 – bus 911 B-3000 Leuven Belgium phone +32-16-330815

Abstract

The historical research-funding model, based on the curiosity and academic interests of researchers, is giving way to new strategic funding models that seek to meet societal needs. We investigated the impact of this trend on health research funded by the two leading funding bodies worldwide, i.e. the National Institutes of Health (NIH) in the United States, and the framework programs of the European Union (EU). To this end, we performed a quantitative analysis of the content of projects supported through programmatic funding by the EU and NIH, in the period 2008-2014 and 2015-2020. We used machine learning for classification of projects as basic biomedical research, or as more implementation directed clinical therapeutic research, diagnostics research, population research, or policy and management research. In addition, we analyzed funding for major disease areas (cancer, cardio-metabolic and infectious disease). We found that EU collaborative health research projects clearly shifted towards more implementation research. In the US, the recently implemented UM1 program has a similar profile with strong clinical therapeutic research, while other NIH programs remain heavily oriented to basic biomedical research. Funding for cancer research is present across all NIH and EU programs, and in biomedical as well as more implementation directed projects, while infectious diseases is an emerging theme. We conclude that demand for solutions for medical needs leads to expanded funding for implementation- and impact-oriented research. Basic biomedical research remains present in programs driven by scientific initiative and strategies based on excellence, but may be at risk of declining funding opportunities.

Keywords: Public funding of science; Funding priorities; FP7; Horizon 2020; Research Project with Complex Structure Cooperative Agreement

Introduction

Expectations of societal benefit is the rationale for public investment in research. The impact of science and research at public institutions on technological development during World War II, inspired and motivated the launch of the National Science Foundation, NSF, in the United States, US, one of the oldest governmental funding agencies (Bush, 1945, 1947). Stimulating frontier science, driven by scientific curiosity and opportunity, was the aim and excellence of the proposed research the lead awarding criteria (Shaw, 2022). To this day, the model of science-led priorities is still predominant in most governmental funding programs of academic research (Boroush, 2020). However, under pressure for enhanced and faster return for economic growth, new models have emerged, such as bringing the private sector together with academia in public-private partnerships (Arnold & Barker, 2022). Other funding mechanisms define strategic priorities, with more explicit endpoints and deliverables, as set out in the concept of missions (Mazzucato, 2018). Societal impact, contributing to the sustainable development goals, has become a major driver for public investment in research (Kastrinos & Weber, 2020). Unlike research funding guided by the interest of researchers and excellence of their proposals, this strategic funding seeks to provide the necessary knowledge to meet society's needs for scientific knowledge in the face of the challenges it faces.

Health and biomedical research in particular carry the expectation of a healthier society as return on investment, with economic perspectives for a healthy workforce and a thriving healthcare industry (Caulfield, 2010; Nathan et al., 2001). In the early 2000's, a noted lack of progress from fundamental biomedical research and discoveries to new treatment, the so-called translational gap (Aarden et al., 2021), has stimulated strategic funding programs in health research, including the creation by NIH of the Clinical and Translational Science Awards (CTSA) Program (Kim et al., 2020; Llewellyn et al., 2020; Reed et al., 2012). The recent Cancer Moonshot (Singer, 2022) in the US and the Mission: Cancer in the European Union (Lawler et al., 2021), are paradigmatic examples of deliverable-oriented funding, and typically engage actors from the so-called quadruple helix, i.e. academia, the private sector or industry, government and society, in this case patients (Miller et al., 2018). More recently, the Covid-19 pandemic and the threat of emerging infectious diseases has further stimulated targeted investment (OECD, 2021). The strategy of priority funding to areas of need, is complemented by two other strategies to stimulate translation. The first is stimulation of collaboration in multi- and crossdisciplinary research and seeking critical mass, in particular for clinical research (Al et al., 2023; Demotes-Mainard & Ohmann, 2005). The second is incentivizing research aiming for implementation of knowledge, such as clinical and diagnostics research and research toward health policies and management (Neta et al., 2015; Roberts et al., 2019).

At EU level, investment in R&D is closely linked to the overall EU political priorities. Amendments to the EU Treaty in the '80s, consolidated the investment in research and innovation by the EU and set out the expectation for economic return. In a 7-year cycle, the EU Regulations on the Framework Programmes, FPs, funding research and innovation, have since laid down defined strategies (Kim & Yoo, 2019; Rodríguez et al., 2013). The content of the FPs is an example of the complexity of the process of agreeing on priority scientific issues and problems to be resolved (Ludwig et al., 2022). Overall features are the emphasis on collaborative cross-border research, and emphasis on economic and societal impact.

In a recent study commissioned by the Foresight Unit STOA of the European Parliament, data indicated that the orientation of collaborative health research projects financed by the FPs has shifted from an approach focused on biomedical research to one oriented towards implementation research for better health and healthcare (Sipido et al., 2022). The study highlighted the need for coherence across the EU and Member States for health research, contrasting the fragmented investment in Europe with the central funding for health research through the National Institutes of Health, NIH, in the US. Although in terms of budget, the EU FPs contribute but a fraction of the total health research investment in Europe, EU funding is unique in its policy-driven strategy and support for international collaboration (Sipido et al., 2022). NIH has its own policies but a common driver for EU and NIH has been the ambition for more translation and implementation of findings for better health (Aarden et al., 2021). Whether there is a convergence in evolution of strategic funding between EU and US, is unknown, as few studies on the evolution of funding of health research in the world are available.

What is known, is that NIH is the largest single funder of health research in the world, followed, although with a gap, by the EU (Viergever & Hendriks, 2016). According to this 2016 study, which had examined the data up to 2013, the EU FPs are strategic research funding but not NIH. Recently it was reported that for the year 2019 the list of top 10 funders was still led by NIH, followed by the EU (Sipido et al., 2022). However, little is known about the content and nature of health research projects financed by NIH or by EU with respect to directionality of research towards more translation and implementation.

Therefore, the aim of our study is to assess evolution of the direction and content of health research funding and compare these two agencies, examining the data in the light of changing policies. To this end we selected two time periods of seven years based on the life cycle of the EU FPs, i.e. projects funded between 2008 and 2014 (FP7), and between 2015 and 2021 (Horizon 2020). We sought to match funding mechanisms for collaborative research between EU FPs and NIH, and examined only

programs with major beneficiaries in public institutions. For the FPs, we thus analyzed projects funded via funded under the pillar or societal challenge 'Health', and for NIH we analyzed projects funded via U01, P01 and UM1. To complement this analysis, we also included projects from programs in health research by single investigators, selected based on excellence and merit only. Using text-based analysis of the project abstracts, we asked whether health research projects were primarily in the area of basic biomedical research or beyond, seeking translation and implementation. We identified the clinical-therapeutic level, as well as the levels of diagnostic-screening, population and risk factor research, and health management and policies. We also gathered evidence on project funding for some major challenging health problems, to inform on prioritization.


Methods


EU and NIH funding programs for collaborative research

The funding program under FP7's Pillar Health and under the Horizon 2020 Societal Challenge Health, finance collaborative projects that respond to strategically defined calls. We identified three funding programs of NIH that share characteristics with these EU programs. The U01 projects, which are defined as "Research Projects-Cooperation Agreements," adhere to the bottom-up scientist-driven funding model, but with a dimension of purpose and goal, and explicitly expected cooperation: '... support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies.' For our analysis, we selected only those U01 projects with two or more principal investigators given our goal of comparing FPs to NIH funding of collaborative projects. P01, which are defined as "Research Program Projects," also follow the researcher-driven funding model and include various research teams led by independent researchers working on interdependent projects, but do not stipulate the cooperation that is expected in the U01. UM1, which are defined as "Research Project with a Complex Structure **Cooperation Agreements**," are in an intermediate position between the strategic financing model and bottom-up financing for research, since depending on the center within the NIH, these projects can originate as response to specific calls or proposals from researchers. The main characteristic is that they are large-scale projects with highly complex structures such as clinical networks or consortiums that require the substantial participation of federal programmatic personnel for support of research activities. It is important to mention that these three NIH funding streams (U01, P01 and UM1) are for extramural research projects, and the distribution of these funds is under the administration of the 27 institutes and centers of NIH. An overview of the elaboration of policies and strategic planning for health research funding through the EU FPs and NIH is given in Supplementary Material 1. For the EU funding through the FPs, we included in the analysis funding through the European Research Council, ERC, a funding channel within the FPs characterized by the absence of defined calls. ERC is a paradigmatic example of the researcher-driven funding model, in which a principal investigator proposes a research project to compete for funding with academic excellence being the only criteria. We incorporate these projects into the analysis because they are the result of a policy decision for investment in excellence-driven research. Thereby they serve as a reference data set without strategic influence on topic selection, only driven by scientific excellence and exemplary for fundamental frontier research.

In total, 26,510 projects were analysed of which 3,704 ERC-LS projects, 1,008 under FP7 pillar Health, 1,216 under Horizon2020 SC1 Health, 9,328 NIH-U01 projects (only projects with two or more

principal investigators), 8,891 P01 projects, and 2,363 UM1 projects. Figure 1 illustrates the associated funding amounts for the two periods under study.





Data sources for project funding and content

As sources of information for EU funding, we used the CORDIS database (https://cordis.europa.eu/) to extract information on health research projects financed by FP7 and Horizon2020, and the datahub of projects funded by the ERC (https://erc.easme-web.eu/). We used RePORTER (https://reporter.nih.gov/) to extract information on health research projects funded by the NIH via U01 (Research Project-Cooperative Agreements), P01 (Research Projects) and UM1 (Research Project with Complex Structure Cooperative Agreement).

Except for the projects financed by the NIH via UM1, which is a relatively recent program (the first projects financed appear in fiscal year 2011), projects were selected for the periods 2008-2014 and 2015-2021.

The three databases used provide a summary description of the projects (title, abstract) financed as well as metadata on the identity of the principal investigator, the beneficiary institutions and the

amount of support. In addition, CORDIS and RePORTER provide information on publications stemming from these projects.

Definition of levels in health research.

In the present study, we use five levels of health research, which are previously well defined in the scientific literature (Fajardo & M Castano, 2016; Nederbragt, 2000; Pratt et al., 2020): **Basic biomedical research** consists of the study of the pathophysiological mechanisms that explain the disease at the sub individual level. This level includes the formulation of potential pharmaceutical or biotechnological therapies that are tested in vitro and animal models. **Clinical-therapeutic research** is related to the development and evaluation of new treatments against diseases, that is, the development of disease interventions at the individual level. This level includes clinical trials phases 1 to 4. **Research on diagnosis and screening** is also clinical research but aimed to the identification of disease in individuals to guide treatment and patient management. **Research on risk factors in the population**, as well as basic biomedical research, seeks to explain the disease, but at a collective level. This research includes the search for genetic, environmental and social determinants or factors of the disease. Finally, **research on health management and policies**, in a similar way to clinical research, seeks to intervene in health problems but through the design, implementation and evaluation of organizational efforts.

Text mining tools and algorithms

The content of the project descriptions were analysed in two complementary workflows as illustrated in Figure 2.




Figure 2. Diagram of the workflow of the analysis of information on projects funded by NIH and FPs. At the top are source data, green indicates steps of analysis and blue resulting data. * Levels of health research: biomedical, clinical, diagnostic, population, and management and health policies.

The first is an exploratory analysis resulting in terms and networks, the second a classification approach using machine learning tools. This analysis was applied for each funding program and period.

Exploratory analysis of research terms and clustering

A first exploratory quantitative content analysis of the projects' description (title and abstract) was carried out using KH Coder, a powerful tool for statistical content analysis based on R, to identify the main terms associated with each program (Higuchi, 2016). For text processing using KH coder we

select the lemmatization option, which allows us to distinguish the parts of speech (nouns, pronouns, proper names, adjectives, verbs, etc) allowing us to map the relationship between terms through cooccurrence networks. The co-occurrence networks were elaborated using only nouns, which facilitated the interpretation and avoided the duplicate appearance of terms with different grammatical functions. For each co-occurrence network, the 120 edges with the strongest Jaccard coefficients were filtered. As a validation of the KH Coder method, we performed a similar analysis using the Leiden and Louvain 'leading eigenvector' and 'edge betweenness communities' algorithms (Supplementary Material 2).

The results of the exploratory content analysis also identified a set of key terms and combinations of terms related to five different levels of research: basic biomedical, clinical therapeutic, diagnostic/prognostic, population and risk factor research, and health policies and management. We then carried out an analysis of the distribution of the terms coded in the five different levels of research in the description of the projects using KH Coder, and generated a heatmap with clustering of funding according these levels of health research.

Classification and distribution of project funding according to levels of research

A sample of 10 representative projects from each research level (basic biomedical, clinical therapeutic, diagnostic/prognostic, population and risk factor research, and health policies and management), 50 in all, was classified based on the expert knowledge of the authors. This sample was then used as starting point to build a model for project classification using KH Coder's Naive Bayes Classifier, a machine learning tool (lwata et al., 2021). A model, in plain terms, is a set of terms with a score related to the probability of being associated with one category or another, built from the examples manually classified based on the expert knowledge of the authors. As the number of examples of manually classified projects increases, a refinement of the capacity of the Bayes classifier model to correctly discern to which level of research a project would belong is foreseeable. However, when in the final round the number of projects classified manually for the construction of the model was doubled from 50 to 100, the distribution of projects classified by research levels among the different funding channels did not show a significant change.

As a subsequent test, a randomized sample of 10 projects for each research level (50 in total) classified by the ML tool were reviewed to verify the degree of agreement between the classification done by machine and the classification done by humans. Hand-classified projects continued to be fed into the model repeatedly until the classification by machine was sufficiently satisfactory. KH Coder automatically re-classified projects previously hand-classified and used for model building to perform cross-validation. This cross-validation resulted in 80 percent of the projects being classified correctly.

We also performed manual cross-validation. In each round of automatic classification we extracted a sample of projects for each of the categories, to manually check if the sample was classified correctly. KH Code classified correctly 82 percent of the projects that the authors verifiedr. Once having a satisfactory classification, an analysis of the distribution of the projects classified in the five levels of health research was carried out, among the different financing programs for the two periods considered (2008-2014 and 2015-2021).

Targeted search for projects addressing disease areas

We also carried out an analysis of the distribution of coded terms in groups of diseases with KH Coder, for which we took advantage of the extensive specialized vocabulary contained in the Medical Subject Headings (MeSH) categories and their input terms, discarding general terms such as cells, tissue or disease and avoiding the repetition of words in the coding. In the case of neoplasms, we use all the entry terms of the "neoplasm" category and all the subcategories and entry terms of "neoplasms by histologic type" and "neoplastic processes." For cardiometabolic diseases we used the MeSH categories "glucose metabolism disorders, "lipid metabolism disorders," "metabolic syndrome," "overnutrition," "heart diseases," and "vascular diseases." Finally, for infectious diseases we used the MeSH categories "bacterial infections and mycoses," "parasitic diseases," and "virus diseases."

In addition to the vocabulary extracted from the MeSH, we used a set of terms associated with each of these groups of diseases generated by ChatGTP, and a set of terms related to cardiovascular diseases used as search criteria by Gal et al (Gal et al., 2019). ChatGPT is a language model based on neural networks trained with huge amounts of textual information capable of generating new texts similar to those produced by humans (Lund & Wang, 2023). Due to its extensive vocabulary and ability to process and generate textual information, ChatGTP has shown in recent studies its usefulness and precision as a tool that helps in the generation of academic document queries (Wang et al., 2023). In our case, we asked ChatGPT to generate a list of key terms related to each of the disease groups. Most of the terms generated by ChatGTP were already included in the set of terms extracted from the MeSH and the additional terms did not provide benefit for the analysis.


Results


Content of research projects funded during successive FPs

For each of the research funding channels analyzed, a network of co-occurrence of highly frequent terms was created, using the Clauset-Newman modularity for clustering (Clauset et al., 2004). Alternative methods of clustering co-occurrence networks such as Leiden and Leuven were tested without significant conceptual differences in the results (Supplementary Material 2).

ERC Life Sciences

ERC funds projects with focus on discovery and ground-breaking science.





As illustrated in Figure 3, for both FPs, the main cluster of terms, by size and centrality, is related to the study of biomolecular and cellular processes, without a specific disease connotation. The second largest cluster has a central node for cancer and while closely related to the biomolecular cluster, it contains many terms related to translation and the development of therapies to treat cancer. It equally changes little with time. Small clusters of terms related to neuroscience, the study of infectious processes and evolutionary processes are present in the two periods. Taken together, there is little change over time.

Health research funding in response to targeted calls

The analysis of the projects funded under the strategic collaborative research for health in the consecutive FPs presents a different picture (Figure 4).




Figure 4. Map of co-occurrence of highly frequent terms in the description of projects financed under the strategic collaborative channels for health research, via FP7, left and Horizon 2020, right.

In the FP7-health co-occurrence network, there is an identifiable cluster (red) that refers to mechanistic biomedical research, but it is closely connected to a cluster (orange) related to clinical-therapeutic research and small cluster that is patient-centered on health care (blue). A separate cluster (turquoise) is related to the area of health management and policies. The Horizon 2020-health co-occurrence network shows a completely different research funding profile. In the first place, a cluster of biomolecular mechanistic research terms is not identifiable. The main cluster, in turquoise, is related to the area of patient and health care management and policies. Another cluster (blue) is related to processes of innovation and commercialization of health technologies. A third, smaller cluster (green) is related to clinical-therapeutic research. In general, a clear dominance of terms refers to levels of research that are focusing on translation, innovation and implementation.

Content of collaborative health research projects funded by NIH

U01 funding

We first examined projects financed by the NIH via UO1 (Figure 5). These projects are collaborative, scientist-driven and focused, with a relatively small budget of less than 1 Mi USD. In the case of the projects financed by the NIH via UO1, the co-occurrence network of terms presents in two large clusters, with a limited number of smaller clusters for the period 2008-2014 (Figure 5, left panel).




Figure 5. Map of co-occurrence of highly frequent terms in the description of projects financed via NIH-U01 (periods 2008-20114, left and 2015-2021, right).

In the 2008-2014 period, the largest of the clusters is made up of exclusively biomolecular and cellular terms (yellow), while the second cluster is a mix of clinical, population, and risk factor terms (green). In the same period, there are also medium-sized clusters related to genomic research (purple) and the development of screening and diagnostic methods (orange). In the period 2015-2021, a large translational research cluster (pink) is observed that connects basic biomedical terms at one pole with clinical terms at the center, and population and health management terms at the other end. Cancer is a prominent term in this cluster. The many smaller clusters in this period are related to specific health problems or population groups.

PO1 funding

P01 projects are collaborative program funding of related projects, but without a strong cooperative agreement. The average amount per project is around 1,5 Mi USD.






Figure 6. Map of co-occurrence of highly frequent terms in the description of projects financed via NIH-P01 (periods 2008-2014, left and 2015-2021, right).

The map for 2008-2014 (Figure 6, left) is constituted by a large cluster (pink) composed of biomedical terms, connected to some clinical-therapeutic terms and cancer. Small scattered clusters relate to demographic groups and specific health problems. The map for 2015-2021 (Figure 6, right) is largely comparable. It has one very large cluster (blue) related to mechanistic molecular and cellular research, whereas the second sizeable cluster relating to therapy and cancer is now seen as separate. In addition to this central structure, small scattered clusters relate to disease processes with variable levels of translation and clinical perspective. E.g., infectious disease is connected to the development of vaccines, diabetes with insulin and a small cluster is about transplantation. This dispersion is probably due to the structure of the NIH, which is made up of institutions specialized in various diseases and population groups.

UM1 funding

Projects financed by the NIH via UM1 are large scale collaborations with multiple activities and budgets of on average 4,4 Mi USD. As the program implementation started only in 2011, the analysis considers projects funded between 2011-2021. The co-occurrence network shows two large clusters and some smaller in the periphery (Figure 7).





One large cluster (blue) is related to genomic research, with terms referring to mechanistic research as well as diagnostics development and technology. Another large cluster (orange) is related to clinical-therapeutic research, with one identifiable topic of infectious disease and several terms related to organizational aspects such as "leadership," "group," "management" and "networks". Scattered minor clusters related to various diseases, population groups and other topics are observed.

Coding of terms in research levels

We established a code relating terms associated with projects to levels of research and analysed the presence of biomedical, clinical-therapeutic, diagnostic-detection, population, and health management and policy within each funding programme. We then examine the differences and similarities between the different funding programs using a cluster analysis that applies the Ward method and uses the Euclidian distance presented as a heat map. (Figure 8).






Figure 8. Heat map and clustering of funding programs according to codified domains of health for research projects in NIH-U01, NIH-P01, UM1 ERC-LS and FP7-health and H2020-health.

The heat map clusters the different funding channels based on the distribution of the terms coded at the levels of research. On the right side of the heatmap there is a cluster formed by projects funded by ERC-LS and NIH-PO1, and includes both periods 2008-2014 and 2015-2021. These four sets of projects are characterized by a high frequency of basic biomedical terms, present in over 90 percent of the projects. Whereas for PO1 projects we see an increase in presence of higher research levels (clinical-therapeutic and population) in the second period, this is not the case for ERC. On the left side of the heat map are clustered NIH-UO1, NIH-UM1 and the FPs. The projects of these funding channels are characterized by a more equitable distribution of the terms coded at the different levels of research. This cluster is in turn divided into two parts. The left subcluster contains the two time periods analyzed for NIH-UO1, which are characterized by a high frequency of biomedical and population research terms, in over 70 percent of the projects, and FP7 with more than 70 percent of its projects containing biomedical terms and close to 60 percent containing population terms and risk factors. The right subcluster is made up of the NIH-UM1 and Horizon-2020, and is characterized by having the lowest percentage of projects with biomedical terms, with a more homogeneous distribution among the different levels of research, consistent with high levels of complexity.

Distribution of projects classified by research levels

Whereas the previous analysis considered the presence of levels of research in the project, it was not a hard classification and did not allow analysis of a more quantitative distribution of levels of research within the program. For this latter analysis, we assigned a project to one level of research according to the predominance of the level of research, using the KH Coder machine-learning tool. The resulting distribution throughout of the different financing channels (Figure 9) shown below is in line with the analysis of coded terms in Figure 8, but in a more quantitative presentation of the main orientation within the programs.





According to the classifier, more than 80 percent of the ERC-LS projects are biomedical research projects while the rest are related to diagnostic research projects and population research and risk factors. Less than three percent of the projects funded via ERC-LS were classified as clinicaltherapeutic or health management and policy research, and this for both periods analysed. In the case of collaborative health research in the FPs, biomedical research projects are a minority fraction. FP7 has a distribution of projects distributed almost equally between the research levels, except for research on population and risk factors with only 10 percent of the projects. In the case of Horizon 2020, more than a third of the projects are classified in the area of health management and policies, followed by diagnostic research with 30 percent, while less than 5 percent are basic biomedical projects. Similarly to ERC-LS, the majority of projects funded by NIH-P01 are basic biomedical research (just over 72 percent in the 2008-2014 period and 67 percent in the 2015-2021 period) followed by population research projects and risk factors. Projects funded by NIH-U01 have a relatively balanced distribution among the different levels of research, although with a modest proportion of research projects on health management and policy (11 percent in both periods). In the case of the NIH-UM1, more than 55 percent of the projects were classified as clinical-therapeutic research, while a third of the projects were divided between basic biomedical research and diagnostic research. The remaining 10 percent of the projects were divided between population research and health management and policies.

Disease orientation of funding

In the term analysis presented in Figures 3 to 7, two diseases areas were prominently represented, i.e. cancer and infectious disease. These areas are also prominent in research policies and reflect the societal challenges they pose. Cardiometabolic disease is also a major health challenge but the topic did not appear strongly in the clusters. In a subsequent analysis, we therefore looked across the funding programs in how far they included research related to these three major disease areas. This analysis was expected to also inform whether specific instruments would be more directed at one or other disease area. The resulting heatmap, clustering funding streams according to the distribution of disease-coded terms, is presented in Figure 10.




Figure 10. *Heat map resulting from clustering of funding programmes according to the presence of terms related to three major diseases areas.*

In this heatmap, UM1 is considered a single cluster because of its strong focus on infectious diseases. After setting aside UM1, interestingly, the clustering groups the US and European funding mechanisms separately suggesting different priorities for disease areas in health research between the NIH and the European Commission. Both the FP7 and H2020 health research programs and the two periods of the ERC-LS are characterized by having a low percentage of projects with terms related to any of the three groups of diseases. In the case of ERC-LS, the terms related to cancer research are most prevalent, in FP7 terms related to infectious diseases and in Horizon 2020, cancer and infectious disease in equal amounts. In NIH funding, excluding UM1, all diseases terms are more prevalent than in EU funding, with a stronger presence of cancer research.

When we examine the heatmap from the perspective of disease areas, it is clear that infectious disease is well represented and at the core of UM1 funding. Infectious disease is also present in the most recent group of P01 projects and to some extent in other programs. Cancer research on the other hand is present across all programs with only FP7 projects having less than 30% terms associated with cancer research. Cardiometabolic disease as expected is less present, with most notably less than 20% of ERC projects having terms related to cardiometabolic disease.

In a final analysis, we examined the level of research within these disease areas, and performed a cross-tabulation between classification by ML versus disease groups (Figure 11).




Figure 11. *Map of cross-tabulation of classifications via ML vs coding of the research groups.*

The strongest association is for therapeutic clinical research with infectious disease (over 60 percent of clinical projects), while about 40 percent of the projects classified as diagnostic and screening research contain terms related to cancer research. Population and risk factors are most prominently associated with cardiometabolic disease.

Discussion

Evolution towards higher levels of health research

Between FP7 and Horizon 2020, the EU funding for research under the strategic destination Health has visibly moved towards a predominance of higher levels of research. Such shift in emphasis is not unexpected, given that the FPs are a financing mechanism for strategic research whose priorities are defined through a negotiation and planning process within the EU institutions of European Commission, Council representing Member States, and Parliament (Kim & Yoo, 2019; Ludwig et al., 2022; Sipido et al., 2022). A review of the strategic plans of both FPs reveals a trend towards research for addressing health problems of the European population, through interventions in at all levels of care as wells preventative medicine. Of particular note is the expansion of research projects on health management and policies in Horizon 2020 with respect to FP7. This trend is expected to increase in the current FP, Horizon Europe (European Commission Directorate-General for Research Innovation, 2021). In contrast, the ERC Life Sciences have maintained a predominant focus of basic biomedical research. Although this may at first glance ensure a balance of funding across the different levels, the evolution has also led to less funding for cross-level, collaborative research under Horizon 2020.

Within NIH, the levels of research within some of the different programs compare to the major funding schemes in EU. P01 is focused mostly on biomedical research, like ERC, and U01 resembles FP7 in the level of research. With an average amount of more than 4 million dollars per project, UM1 is the largest NIH funding scheme, in the same order of magnitude as the health research projects financed by FP7 and Horizon 2020. UM1 has however, a more singular focus on clinical therapeutic research and infectious disease. Across the two periods of study, NIH programs are stable in their profile, but there is a shift in funding allocation between programs (Supplementary Material 3, Fig. SM3.1). Notable is how funding into the higher-level scheme of U01 has increased over the years, with less investment into P01, which funds predominantly basic biomedical research, and the emergence of the UM1 scheme after 2015.

Although investigation of continuity of funding was not within the aims of the study, the NIH database includes information about whether awards are a continuation or a new application, and terms in the project description can likewise indicate continuity of topic, including in UO1. These data suggest opportunities for continuity of high-level research within the NIH funding scheme. For EU funding, in contrast, given that projects are awarded through targeted calls, researchers are less likely to have a continued funding of the same research topic. ERC is not a long-term funding channel either, though outstanding investigators may be repetitively funded when presenting a novel groundbreaking and competitive proposal.

Differences between NIH and EU also emerge in the programs funding biomedical research. The ERC granting scheme of the EU is unique in its scale of funding to a single PI for risk-taking research and vastly exceeds NIH funding through single PI schemes. In contrast, NIH supports biomedical research in collaborative projects. Another NIH strategy for fostering ground-breaking research lies in providing a longer time window of funding. NIH has two dedicated programs for long-term funding for outstanding investigators, R35 and R37 (Supplementary Material 3). These programs are extensions of investigator-driven programs and content-wise mostly basic biomedical research (Figs. SM3.2-6). The most recent program, R35, provides a long term support to outstanding researchers, and is a growing program (Fig. SM3.1). In contrast to ERC, the funding is mostly determined on merit, rather than project-based. This comparison, though preliminary, opens an interesting window on different strategies for investment in basic biomedical research.

In summary, both agencies appear to move towards higher-level research but through different approaches. The focus and strategy for EU FPs are adapted over time, whereas NIH maintains stability within the programs and moves forward through introducing novel programmatic opportunities for large-scale, higher-level, research. Both approaches do converge however in pushing for solutions addressing major health challenges, through exploring means for better prevention and treatment.

Evolution and EU-NIH differences in priority setting for disease areas

The terms analysis of content of the projects funded, did not lead to large, disease-related clusters in the maps, except for the identification of cancer research and infectious-disease related research. Other diseases are identifiable in smaller clusters, but more quantitative interpretation of their prevalence would require further analysis. Interestingly, a disease-based clustering of funding separated EU and NIH funding with overall stronger presence of disease terms in NIH funding. A likely explanation is the US strategy of funding through institutes. The allocation of funds to the 27 institutes is primarily decided within NIH (Supplementary Material 1). Evolution of over time shows continued high investment in cancer and infectious disease, above investment in cardiovascular disease (Fig. SM1.1). The concerns about underinvestment in cardiovascular disease of recent years were primarily based on the lack of new treatments in relation to the growing epidemic (Califf, 2021). A publication analysis also pointed in the same direction (Rafols et al., 2022; van de Klippe et al., 2022). Analysis of different levels in the present study points towards larger investment in preventative research than in discovery research. This would continue the trend noted in a

publication analysis for the years up to 2013 which noted particular growth in the area of population sciences (Gal et al., 2019).

Future trends for strategic investment in health research

In the drive towards more translation and innovation, the EU launched several new programs that made use of public-private and other partnerships, and where priorities are set in a multi-stakeholders model. The earliest program was the Innovative Medicines' Initiative, IMI, under FP7, continued in Horizon 2020 as IM and in Horizon Europe as Innovative Health Initiatives, to include medical technologies (Laverty & Meulien, 2019). The recently introduced European Innovation Council is another program to facilitate throughput of discovery to innovative healthcare (European Innovation Council, 2022).

In the US, strategic top-down public funding schemes for advanced health research are the Patient-Centered Outcomes Research Institute (PCORI) and Congressionally Directed Medical Research Programs (CDMRP), an office within the U.S. Army Medical Research and Materiel Command. PCORI funds comparative research projects of clinical effectiveness with a strategic prioritization centered on the patient (Forsythe et al., 2019). The CDMRP funds high-risk/high-reward projects to address health problems defined by the US Congress based on an annual strategy generated in consensus with patients, family members and caregivers (National Academies of Sciences & Medicine, 2017). For the current fiscal year CDMRP will finance 35 research programs for a total amount of 1.5 billion dollars, a magnitude comparable to the health programs of the FPs (Department of Defense, 2022). The recently launched Advanced Research Projects Agency for Health (ARPA-H) will have a budget of 6.5 billion dollars for high-risk/reward research, without specific topics prioritized but pushing for translation and innovation (Thorp, 2022).

For many years the US also has engaged for investment in diseases where need was considered the highest with notable examples of HIV research and cancer. At this moment, the Cancer Moonshot 2.0, whose objective is to reduce cancer mortality by half in the next 25 years, is contemplating for 2024 an investment of 7.8 billion dollars just for the NCI (Mervis, 2023). At a smaller scale, the Accelerating Access to Critical Therapies for ALS Act that requires the Food and Drug Administration (FDA) to fund research projects for the development of interventions for the prevention, diagnosis, and treatment of rare neurodegenerative diseases (Lynch et al., 2022). It will be interesting to include these new initiatives on financing health research in subsequent analyses to trace their evolution and determine if they adjust to the needs and health problems of the population.

Virtues and limitations of the study

We present in the main manuscript clustering data obtained by one approach only. As validation, we have also analyzed the clustering of terms using different algorithms, which are well established for bibliometric analysis (Supplementary Material 2). The results show high concordance with the analysis presented in Figures 3 through 6.

In the present analysis we only included core funding that primarily serves public institutions and could be analysed for trends over a longer period. The two health research funding agencies were chosen for the analysis because of their leading role in the global landscape, their strategic approach guided by governmental decisions, and accessible documentation. Future analysis would usefully look into other funding agencies with large financial impact, including charities such as Wellcome with a budget close to that of EU health research investment.

Within the large NIH budget, we excluded the largest funding scheme being the RO1 grants. This choice was motivated by the nature of RO1 funding, i.e. scientist-driven and mostly led by single PI. The NIH budget we considered, nevertheless is considerably larger than the budget invested by EU. Indeed, the largest spending in Europe is through national funding agencies. However, with some exceptions, the data at national level for the analysis performed here are difficult to obtain. It is noteworthy that European national funding mechanisms have also initiated funding schemes to promote translation and innovation, and collaborative research.

In general, studies on financing for health research focus on the analysis of beneficiary institutions and researchers (Hoppe et al., 2019; Madsen & Aagaard, 2020; Ross et al., 2022) and on the final products of these projects, such as publications and patents (Fajardo-Ortiz et al., 2022; Mugabushaka et al., 2022). As such, our study addresses a knowledge gap regarding which research topics (groups of diseases) are financed and from what focus or level of research (basic, clinical, population-based, and management and health policies). The strength compared to publications research, is the short time lag after funding decision, with publications following only with several years of delay, and the direct link to the actual investment, compared to the uncertainty when linking publications to funding. The information gathered tells about the funders' aims and expectations, though it is quite possible that the outcomes eventually will diverge from the funding aims. This will be the topic of future research.

Conclusions

Both EU funding and NIH funding show a trend towards higher-level research funding. Different mechanisms operate at EU and NIH, with a tradition of large and policy-directed programs in the EU FPs, while in the US, strongly directed, large programs are only recently emerging. High investment in cancer is present in directed strategic as well as bottom-up biomedical research, with emergence of infectious disease as novel focus. Drivers are medical urgency as well as public and political support, with new initiatives expected to expand the outcome and impact-oriented research funding. Basic biomedical research is found predominantly in programs driven by scientific initiative and strategies based on excellence, and may be in need of renewed strategies to address a risk of declining funding opportunities.

Acknowledgments: This research was supported exclusively with the resources of the Katholieke Universiteit Leuven

References

- Aarden, E., Marelli, L., & Blasimme, A. (2021). The translational lag narrative in policy discourse in the United States and the European Union: a comparative study. *Humanities and Social Sciences Communications*, 8(1), 1-9.
- Al, M., Levison, S., Berdel, W. E., & Andersen, D. Z. (2023). Decentralised elements in clinical trials: recommendations from the European Medicines Regulatory Network. *Lancet*, 401(10385), 1339.
- Arnold, E., & Barker, K. E. (2022). What past changes in Swedish policy tell us about developing thirdgeneration research and innovation governance. In *Smart Policies for Societies in Transition* (pp. 59-86). Edward Elgar Publishing.
- Boroush, M. (2020). Research and Development: US Trends and International Comparisons. Science and Engineering Indicators 2020. NSB-2020-3. *National Science Foundation*.
- Bush, V. (1945). *Science, the endless frontier. A report to the President*. United States Government Printing Office.
- Bush, V. (1947). A National Science Foundation: Statement before the Committee on Interstate and Foreign Commerce, House of Representatives, March 7, 1947. *Science*, *105*(2725), 302-305.
- Califf, R. M. (2021). Avoiding the Coming Tsunami of Common, Chronic Disease. *Circulation*, 143(19), 1831-1834. <u>https://doi.org/doi:10.1161/CIRCULATIONAHA.121.053461</u>
- Caulfield, T. (2010). Stem cell research and economic promises. *Journal of Law, Medicine & Ethics,* 38(2), 303-313.
- Clauset, A., Newman, M. E., & Moore, C. (2004). Finding community structure in very large networks. *Physical review E*, 70(6), 066111.
- Demotes-Mainard, J., & Ohmann, C. (2005). European Clinical Research Infrastructures Network: promoting harmonisation and quality in European clinical research. *Lancet*, *365*(9454), 107-108.
- Department of Defense. (2022). *Fiscal Year 2023 CDMRP Research Funding* <u>https://cdmrp.health.mil/pubs/press/2023/funding_press_release23</u>

- European Commission Directorate-General for Research Innovation. (2021). *Horizon Europe : strategic plan 2021-2024*. Publications Office of the European Union. <u>https://doi.org/doi/10.2777/083753</u>
- European Innovation Council. (2022). EIC Pathfinder Challenge: Towards the Healthcare Continuum: technologies to support a radical shift from episodic to continuous healthcare. <u>https://eic.ec.europa.eu/eic-funding-opportunities/calls-proposals/eic-pathfinder-challenge-towards-healthcare-continuum-technologies-support-radical-shift-episodic_en</u>
- Fajardo-Ortiz, D., Hornbostel, S., de Wit, M. M., & Shattuck, A. (2022). Funding CRISPR: Understanding the role of government and philanthropic institutions in supporting academic research within the CRISPR innovation system. *Quantitative Science Studies*, 3(2), 443-456. <u>https://doi.org/10.1162/qss_a_00187</u>
- Fajardo, D., & M Castano, V. (2016). Hierarchy of knowledge translation: from health problems to adhoc drug design. *Current Medicinal Chemistry*, 23(26), 3000-3012.
- Forsythe, L. P., Carman, K. L., Szydlowski, V., Fayish, L., Davidson, L., Hickam, D. H., Hall, C., Bhat, G., Neu, D., & Stewart, L. (2019). Patient engagement in research: early findings from the Patient-Centered Outcomes Research Institute. *Health Affairs*, 38(3), 359-367.
- Gal, D., Thijs, B., Glänzel, W., & Sipido, K. R. (2019). Hot topics and trends in cardiovascular research. *European Heart Journal*, 40(28), 2363-2374.
- Higuchi, K. (2016). KH Coder 3 reference manual. Kioto (Japan): Ritsumeikan University.
- Hoppe, T. A., Litovitz, A., Willis, K. A., Meseroll, R. A., Perkins, M. J., Hutchins, B. I., Davis, A. F., Lauer, M. S., Valantine, H. A., & Anderson, J. M. (2019). Topic choice contributes to the lower rate of NIH awards to African-American/black scientists. *Science Advances*, 5(10), eaaw7238.
- Iwata, R., Kuramoto, K., & Kumagai, S. (2021). Extracting Potential Innovators Using Innovator Scores and Naive Bayes Classifier. 2021 IEEE 10th Global Conference on Consumer Electronics (GCCE),
- Kastrinos, N., & Weber, K. M. (2020). Sustainable development goals in the research and innovation policy of the European Union. *Technological Forecasting and Social Change*, *157*, 120056.
- Kim, J., & Yoo, J. (2019). Science and technology policy research in the EU: from Framework Programme to HORIZON 2020. *Social Sciences*, 8(5), 153.
- Kim, Y. H., Levine, A. D., Nehl, E. J., & Walsh, J. P. (2020). A bibliometric measure of translational science. *Scientometrics*, 125(3), 2349-2382. <u>https://doi.org/10.1007/s11192-020-03668-2</u>
- Laverty, H., & Meulien, P. (2019). The Innovative Medicines Initiative– 10 years of public-private collaboration. *Frontiers in Medicine*, *6*, 275.
- Lawler, M., De Lorenzo, F., Lagergren, P., Mennini, F. S., Narbutas, S., Scocca, G., Meunier, F., & European Academy of Cancer, S. (2021). Challenges and solutions to embed cancer survivorship research and innovation within the EU Cancer Mission. *Molecular Oncology*, 15(7), 1750-1758. <u>https://doi.org/10.1002/1878-0261.13022</u>
- Llewellyn, N., Carter, D. R., DiazGranados, D., Pelfrey, C., Rollins, L., & Nehl, E. J. (2020). Scope, influence, and interdisciplinary collaboration: the publication portfolio of the NIH Clinical and Translational Science Awards (CTSA) Program from 2006 through 2017. *Evaluation and the Health Professions*, 43(3), 169-179.
- Ludwig, D., Blok, V., Garnier, M., Macnaghten, P., & Pols, A. (2022). What's wrong with global challenges? *Journal of Responsible Innovation*, *9*(1), 6-27.
- Lund, B. D., & Wang, T. (2023). Chatting about ChatGPT: how may AI and GPT impact academia and libraries? *Library Hi Tech News*.
- Lynch, H. F., Morris, S., & Andrews, J. A. (2022). Access to investigational drugs for patients with amyotrophic lateral sclerosis in the USA. *Lancet Neurology*, *21*(7), 593-594.
- Madsen, E. B., & Aagaard, K. (2020). Concentration of Danish research funding on individual researchers and research topics: Patterns and potential drivers. *Quantitative Science Studies*, 1(3), 1159-1181. <u>https://doi.org/10.1162/qss_a_00077</u>

- Mazzucato, M. (2018). *Mission-oriented research & innovation in the European Union : a problemsolving approach to fuel innovation-led growth*. Publications Office. <u>https://doi.org/doi/10.2777/360325</u>
- Mervis, J. (2023). Biden backs science in 2024 spending blueprint. *Science*, *379*(6637), 1078. https://doi.org/10.1126/science.adh8293
- Miller, K., McAdam, R., & McAdam, M. (2018). A systematic literature review of university technology transfer from a quadruple helix perspective: toward a research agenda. *R&D Management*, 48(1), 7-24. <u>https://doi.org/10.1111/radm.12228</u>
- Mugabushaka, A.-M., van Eck, N. J., & Waltman, L. (2022). Funding COVID-19 research: Insights from an exploratory analysis using open data infrastructures. *Quantitative Science Studies*, 3(3), 560-582. <u>https://doi.org/10.1162/qss_a_00212</u>
- Nathan, D. G., Fontanarosa, P. B., & Wilson, J. D. (2001). Opportunities for medical research in the 21st century. *JAMA*, *285*(5), 533-534.
- National Academies of Sciences, E., & Medicine. (2017). Evaluation of the congressionally directed medical research programs review process.
- Nederbragt, H. (2000). The biomedical disciplines and the structure of biomedical and clinical knowledge. *Theoretical Medicine and Bioethics*, *21*, 553-566.
- Neta, G., Sanchez, M. A., Chambers, D. A., Phillips, S. M., Leyva, B., Cynkin, L., Farrell, M. M., Heurtin-Roberts, S., & Vinson, C. (2015). Implementation science in cancer prevention and control: a decade of grant funding by the National Cancer Institute and future directions. *Implementation Science*, 10, 1-10.
- OECD. (2021). OECD Science, Technology and Innovation Outlook 2021. https://doi.org/doi:https://doi.org/10.1787/75f79015-en
- Pratt, B., Wild, V., Barasa, E., Kamuya, D., Gilson, L., Hendl, T., & Molyneux, S. (2020). Justice: a key consideration in health policy and systems research ethics. *Bmj Global Health*, *5*(4), e001942.
- Rafols, I., Yegros, A., van de Klippe, W., & Willemse, T. (2022). Mapping Research on Cardio-Metabolic Diseases. *SocArXiv*. <u>https://doi.org/10.31235/osf.io/zn5gf</u>
- Reed, J. C., White, E. L., Aubé, J., Lindsley, C., Li, M., Sklar, L., & Schreiber, S. (2012). The NIH's role in accelerating translational sciences. *Nature Biotechnology*, *30*(1), 16-19.
- Roberts, M. C., Clyne, M., Kennedy, A. E., Chambers, D. A., & Khoury, M. J. (2019). The current state of funded NIH grants in implementation science in genomic medicine: a portfolio analysis. *Genetics in Medicine*, *21*(5), 1218-1223.
- Rodríguez, H., Fisher, E., & Schuurbiers, D. (2013). Integrating science and society in European Framework Programmes: Trends in project-level solicitations. *Research Policy*, *42*(5), 1126-1137.
- Ross, M. B., Glennon, B. M., Murciano-Goroff, R., Berkes, E. G., Weinberg, B. A., & Lane, J. I. (2022). Women are credited less in science than men. *Nature*, *608*(7921), 135-145. <u>https://doi.org/10.1038/s41586-022-04966-w</u>
- Shaw, J. (2022). There and back again: Revisiting Vannevar Bush, the linear model, and the freedom of science. *Research Policy*, *51*(10), 104610.
- Singer, D. S. (2022). A new phase of the Cancer Moonshot to end cancer as we know it. *Nature Medicine*, *28*(7), 1345-1347. <u>https://doi.org/10.1038/s41591-022-01881-5</u>
- Sipido, K., Fajardo, D., Vercruysse, T., Glänzel, W., & Veugelers, R. (2022). *Fostering coherence in EU health research: Strengthening EU research for better health* (978-92-846-9805-9).
- Thorp, H. H. (2022). Will ARPA-H work? *Science*, *376*(6590), 223-223. https://doi.org/10.1126/science.abq4814
- van de Klippe, W., Yegros, A., Willemse, T., & Rafols, I. (2022). Priorities in research portfolios: why more upstream research is needed in cardiometabolic and mental health. *SocArXiv*. <u>https://doi.org/10.31235/osf.io/xrhgd</u>
- Viergever, R. F., & Hendriks, T. C. (2016). The 10 largest public and philanthropic funders of health research in the world: what they fund and how they distribute their funds. *Health Research Policy and Systems*, 14(1), 1-15.

Wang, S., Scells, H., Koopman, B., & Zuccon, G. (2023). Can chatgpt write a good boolean query for systematic review literature search? *arXiv preprint arXiv:2302.03495*.

Supplementary Material 1 – EU and NIH funding policies and strategic planning

1. NIH

The process of establishing funding policies at the NIH is complex and involves three levels: a first level is the NIH-wide general planning exercises, which have only taken place on three occasions for the fiscal periods 1991-1992, 2016-2020 and 2021- 2024. A second level would be strategic planning focused on a specific health problem or scientific challenge to be addressed by the NIH as a whole. A third level would be the strategic planning exercises of the centers that make up the NIH. Not all NIH centers conduct these planning exercises, and those that do vary in terms of their scope and length of time.

1.1. NIH-wide strategic planning

The NIH mission has two components: one to support basic research "to seek fundamental knowledge about the nature and behaviour of living systems" and another that promotes "the application of that knowledge to enhance health, lengthen life, and reduce illness and disability (National Institutes of Health, 2017)." Although the NIH is "largely untargeted (but earmarked for broad areas), with smaller targeted and organizational funding streams (Viergever & Hendriks, 2016)" it is possible to note a growing trend towards strengthening strategic funding n the recent NIH-wide strategic planning exercises (National Institutes of Health, 2015, 2020b). As mentioned above, NIH-wide strategic planning exercises have been conducted only three times in NIH history: in the years 1991-1992 and for the fiscal periods 2016-2020 and 2021-2024. It is important to note that these last two global strategic planning exercises at the NIH stem from a mandate from the US Congress, which provided legislative direction for priority setting (Morciano et al., 2020). The NIH-wide planning process is based on a combination of internal and external consultations, the first with representatives of the centers and institutes and the director's advisory committee, and the latter with the scientific community, industry and the public (Morciano et al., 2020).

The planning exercise for the period 1991-1992 exhibited a tension between institutional leadership that aspired to put the United States ahead in terms of science and technology in the biomedical field, and the research community that feared an abandonment of researcher-driven research despite the fact that the planning exercise included the participation of nearly 2,000 scientists (Palca, 1992). The 1992 plan consisted primarily of six "trans-NIH" objectives: critical science and technology, critical health needs, intellectual capital, research capacity, stewardship of public resources, and public trust. The definition of which are the critical technologies and research areas (immunology and molecular medicine, vaccines and biotechnology) and which are the health needs that must be addressed generated points of contention between the leadership of the NIH and the scientific community (Palca, 1992). Both the criticisms of the design and implementation of this first NIH strategic planning exercise likely discouraged further global planning efforts for the next two decades.

There are important differences between the two recent NIH strategic planning exercises regarding the definition of fundamental research and the priorities regarding treatment development and the focus of research for health promotion and disease prevention. In the strategic planning exercise for the 2016-2020 period, fundamental research is defined as "basic biological research that generates

the knowledge of how living systems work at the molecular, cellular, and organismal level (National Institutes of Health, 2015)" while in the planning for the 2021-2025 period, fundamental research is understood as "basic biological, behavioural, and social research that generates the knowledge of how living systems work at the molecular, cellular, organismal, behavioural, and social levels (National Institutes of Health, 2020b)." This represents an extension of the traditional reductionist biomedical paradigm focused on the biomolecular and cellular explanation of the disease and on the subsequent development of pharmacological interventions, which has also been observed in the transition between FP7-health and Horizon-Health of the Commission European (Sipido et al., 2022). Among the priority areas for the development of health treatments and interventions added to the strategic planning for the 2021-2026 period, attention to emerging public health problems such as COVID-19, Zika, Ebola, and opioid addiction in the USA (National Institutes of Health, 2020b). On the other hand, in the area of research for health promotion and disease prevention, the health needs of disadvantaged populations will be prioritized, seeking to reduce health inequities in the United States (National Institutes of Health, 2020b). Taken together, recent NIH strategic planning exercises imply a greater emphasis on public health problems affecting the US population from a perspective that goes beyond the biomedical paradigm and includes support for interdisciplinary research with the involvement of the social sciences.

It is important to mention that these NIH strategic planning exercises as a whole derive from a congressional mandate expressed in the Consolidated and Further Continuing Appropriations Act, 2015, which dictates that "NIH shall submit to Congress an NIH-wide 5-year scientific strategic plan as outlined in sections 402(b)(3) and 402(b)(4) of the PHS Act no later than 1 year after enactment of this Act." The United States Conciliation and Appropriation Acts are a type of spending bill called omnibus because they are a packaging of a multiplicity of ordinances issued under the pressure of a deadline at the end of the legislative process without further discussion.

Regarding research funding managed by the main centers that make up the NIH such as the National Cancer Institute (NCI), the National Institute of Allergy and Infectious Diseases (NIAID), the National Heart, Lung, and Blood Institute (NHLBI), the National Institute of General Medical Sciences (NIGMS), and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) we can observe a stable growth affected by external factors such as the Recovery Act of 2009 that supposed an increase in the financing of the institutes in the period 2009-2010 (*Figure SM1.1*). NCI has held the largest budget for many years. The aspect that probably stands out the most is the increase in the NIAID budget in the 2020-2021 period, even exceeding the NCI, probably as a response to the COVID-19 pandemic. Also of note is the growth in NHLBI funding in the 2019-2021 period, a possible response to the concern about limited innovation despite the impact of cardiovascular disease (Nicholls, 2018).




Figure SM1.1. Evolution of funding for health research administered by the NIAID, the NHLBI, the NIGMS and the NIDDK in the period 2008-2021.

1.2. Topical and Institute planning at the NIH

Topical strategic planning processes at the NIH are quite heterogeneous in terms of their origin and scope. For example, the NIH Strategic Plan for HIV and HIV-Related Research for fiscal year 2021-2025 stems from a 2019 presidential proposal to reduce new HIV infections by 90 percent within a decade (National Institutes of Health, 2019). On the other hand, this plan is the product of the planning and coordination work of the NIH Office of AIDS Research, which coordinates the efforts of the NIH as a whole in the fight against HIV-AIDS and which, for the first time in its history, elaborates a five year plan (National Institutes of Health, 2019). Similarly, the NIH Minority Health and Health Disparities Strategic Plan 2021–2025 was prepared by a central office charged with coordinating NIH efforts in this area: the National Institute on Minority Health and Health Disparities (NIMHD). Unlike the case for HIV strategic planning, however, NIMHD-assisted planning efforts are supported by a legal mandate contained in the Patient Protection and Affordable Care Act that directs the NIH director to "plan, coordinate, review, and evaluate research and other activities" conducted by the NIH on the issue of health inequalities (National Institutes of Health, 2021). At another extreme are strategic planning exercises that, although supported by a plurality of expert opinions, the participation of stakeholders, and with the support of the director of the NIH, do not have the same level of support as a presidential policy or a mandate from the congress. Such are the cases of the 2020–2030 Strategic Plan for NIH Nutrition Research (National Institutes of Health, 2020a) or the Action Plan for Liver Disease Research (Hoofnagle, 2004), which are limited to serving as a guide or source of policy options. In general, NIH strategic planning by themes focuses on responding to specific health problems, societal challenges, or the emergence of disruptive technologies, seeking to satisfy needs for scientific knowledge and technologies that are not sufficiently addressed by the NIH. The strategic planning that each of the NIH centers carries out is diverse in terms of its temporality and scope. The National Cancer Institute (NCI), for example, does not have a proper strategic planning document, but each year submits to the US Congress a budget plan that identifies its research priorities and areas of opportunity (National Cancer Institute, 2019). It is interesting to note that NCI's 2024 budget plan seeks to align with the President's Cancer Moonshot 2.0 initiative (National Cancer Institute, 2023). The National Heart, Lung, and Blood Institute (NHLBI) for their part have a strategic vision that is not limited to a predetermined period of time, but rather is a continuous and adaptive process of incorporating new ideas into the research program of the center (National Heart Lung and Blood Institute, 2016). Workshops with stakeholders can support strategic intitiatives (e.g. https://www.nhlbi.nih.gov/events/2022/2022-nhlbi-workshop-artificial-intelligencecardiovascular-imaging-translating-science) and incentivize funding in topical areas (e.g. https://www.nhlbi.nih.gov/events/2022/current-and-future-research-needs-era-highly-effectivemodulator-therapies-cystic). In the case of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the center's planning is articulated and guided by NIH-wide planning in its areas of expertise in addition to conducting a five-year overall strategic planning exercise (National Institute of Diabetes and Digestive and Kidney Diseases, 2021). In general, strategic planning at the centers that make up the NIH is supported by the ideas of a diversity of scientific experts and interested parties, and serves as flexible guidelines.

2. Setting funding policy for health research in the FPs

The FPs are the central component of the European Union's supranational policy on science, technology and innovation, with the thematic area of health being an important part of the FPs throughout its various iterations. The PFs are supported by a regulation, prepared by the European Commission, reviewed and amended by the European parliament and the Council of the European Union (Council of Ministers), leading to the final decision on the regulation, which has a 7-year lifetime (see e.g.for Horizon 2020 https://eur-lex.europa.eu/eli/reg/2013/1291/oj). In the years of preparation of a new FP, many stakeholders' organizations give input to the European Commission and Parliament and Council also have consultative bodies. The FP regulation, i.e. the political decision, defines the objectives and priorities of the FPs as well as their rules for participation and dissemination. A strategic planning and work programmes with shorter life cycle further refine and translate the regulation in a concrete funding program. The Directorate RTD of the European Commission, in collaboration with other Directorates and services is in charge of this implementation, with input from representatives of Member States. In general, the FPs have been oriented from their beginnings to promote the economic growth of the European Union through innovation. However, since the FP4 the central objectives have been progressively expanded to include other goods such as the health of the population and the protection of the environment, accentuating this trend in the last 3 FPs until reaching the definition of the social challenges in the Horizon 2020 and the incorporation of the sustainable development objectives in Horizon Europe (Kastrinos & Weber, 2020). This expansion can be observed in the evolution of the health area of the last three FPs. In the FP7 the area of health is seen as a theme whose objective is to improve the health of the European population while promoting the competitiveness of health-related industries. FP7-health is composed of three pillars: (1) biotechnology and medical technologies (2) translational research, and (3) optimization of health care delivery (European Commission Directorate-General for Research Innovation, 2008). In Horizon 2020, health is considered a societal challenge with an emphasis on demographic change and well-being. In this way, the objectives and policy drivers are expanded to include the fight against emerging diseases and antimicrobial resistance, attention to the needs of the most vulnerable groups and those affected by chronic diseases, and mitigation of the effects of pollution and climate change in health (Lewandowska, 2022). At Horizon Europe, the

health area is part of a synergistic cluster of research and innovation activities and is organized around six expected results or destinations: (1) "staying healthy in a rapidly changing society," (2) "living and working in a health-promoting environment," "tackling diseases and reducing disease burden," (4) "Ensuring access to innovative, sustainable and high-quality health care," (5) "Unlocking the full potential of new tools, technologies and digital solutions for a healthy society," and (6) "Maintaining an innovative, sustainable and globally competitive health-related industry" (European Commission Directorate-General for Research Innovation, 2021). Another characteristic of the strategic plan of the Horizon Europe health cluster is the search for synergies with other European policies in the convergence of health, research and innovation, such as the EU4Health program and the Europe's Beating Cancer Action Plan (European Commission Directorate-General for Research Innovation, 2021). On the other hand, although the promotion of synergy with the European Health Emergency Preparedness and Response Authority (HERA) is not expressly mentioned in the Horizon Europe Strategic Plan, HERA is part of the governance structure of Horizon Europe (Renda et al., 2023). Furthermore, synergy with HERA is a priority component of the Horizon Europe Work Program 2023-2024, which contemplates "investing in research into better management of epidemics, adaptable clinical networks for drugs and vaccines and better understanding of the emergence of cross-border health threats" through various calls. Another example of synergy mechanisms with Horizon Europe is the Digital Europe Program, which serves as a strategic financing policy for innovation in the areas of supercomputing, artificial intelligence, cybersecurity and other digital technologies, and among whose funding actions it includes jointly with Horizon Europe the consolidation of the Health data space (European Commission, 2023).

Annex references

- Aarden, E., Marelli, L., & Blasimme, A. (2021). The translational lag narrative in policy discourse in the United States and the European Union: a comparative study. *Humanities and Social Sciences Communications*, 8(1), 1-9.
- Al, M., Levison, S., Berdel, W. E., & Andersen, D. Z. (2023). Decentralised elements in clinical trials: recommendations from the European Medicines Regulatory Network. *Lancet*, 401(10385), 1339.
- Arnold, E., & Barker, K. E. (2022). What past changes in Swedish policy tell us about developing thirdgeneration research and innovation governance. In *Smart Policies for Societies in Transition* (pp. 59-86). Edward Elgar Publishing.
- Boroush, M. (2020). Research and Development: US Trends and International Comparisons. Science and Engineering Indicators 2020. NSB-2020-3. *National Science Foundation*.
- Bush, V. (1945). *Science, the endless frontier. A report to the President*. United States Government Printing Office.
- Bush, V. (1947). A National Science Foundation: Statement before the Committee on Interstate and Foreign Commerce, House of Representatives, March 7, 1947. *Science*, *105*(2725), 302-305.
- Califf, R. M. (2021). Avoiding the Coming Tsunami of Common, Chronic Disease. *Circulation*, 143(19), 1831-1834. <u>https://doi.org/doi:10.1161/CIRCULATIONAHA.121.053461</u>
- Caulfield, T. (2010). Stem cell research and economic promises. *Journal of Law, Medicine & Ethics,* 38(2), 303-313.
- Clauset, A., Newman, M. E., & Moore, C. (2004). Finding community structure in very large networks. *Physical review E*, *70*(6), 066111.

- Demotes-Mainard, J., & Ohmann, C. (2005). European Clinical Research Infrastructures Network: promoting harmonisation and quality in European clinical research. *Lancet*, *365*(9454), 107-108.
- Department of Defense. (2022). *Fiscal Year 2023 CDMRP Research Funding* <u>https://cdmrp.health.mil/pubs/press/2023/funding_press_release23</u>
- European Commission. (2023). ANNEX to the Commission Implementing Decision on the financing of the Digital Europe Programme and the adoption of the work programme for 2023 - 2024 and amending the Commission Implementing Decision C(2021) 7914 on the adoption of the multiannual work programme for 2021-2022. Retrieved from https://ec.europa.eu/newsroom/dae/redirection/document/94609
- European Commission Directorate-General for Research Innovation. (2008). *Health research in FP7*. Publications Office.
- European Commission Directorate-General for Research Innovation. (2021). *Horizon Europe : strategic plan 2021-2024*. Publications Office of the European Union. <u>https://doi.org/doi/10.2777/083753</u>
- European Innovation Council. (2022). EIC Pathfinder Challenge: Towards the Healthcare Continuum: technologies to support a radical shift from episodic to continuous healthcare. <u>https://eic.ec.europa.eu/eic-funding-opportunities/calls-proposals/eic-pathfinder-challenge-towards-healthcare-continuum-technologies-support-radical-shift-episodic_en</u>
- Fajardo-Ortiz, D., Hornbostel, S., de Wit, M. M., & Shattuck, A. (2022). Funding CRISPR: Understanding the role of government and philanthropic institutions in supporting academic research within the CRISPR innovation system. *Quantitative Science Studies*, *3*(2), 443-456. https://doi.org/10.1162/qss a 00187
- Fajardo, D., & M Castano, V. (2016). Hierarchy of knowledge translation: from health problems to adhoc drug design. *Current Medicinal Chemistry*, 23(26), 3000-3012.
- Forsythe, L. P., Carman, K. L., Szydlowski, V., Fayish, L., Davidson, L., Hickam, D. H., Hall, C., Bhat, G., Neu, D., & Stewart, L. (2019). Patient engagement in research: early findings from the Patient-Centered Outcomes Research Institute. *Health Affairs*, 38(3), 359-367.
- Gal, D., Thijs, B., Glänzel, W., & Sipido, K. R. (2019). Hot topics and trends in cardiovascular research. *European Heart Journal*, 40(28), 2363-2374.
- Higuchi, K. (2016). KH Coder 3 reference manual. *Kioto (Japan): Ritsumeikan University*.
- Hoofnagle, J. H. (2004). Action Plan for Liver Disease Research. *Hepatology*, 40(6), 1240. https://doi.org/10.1002/hep.20525
- Hoppe, T. A., Litovitz, A., Willis, K. A., Meseroll, R. A., Perkins, M. J., Hutchins, B. I., Davis, A. F., Lauer, M. S., Valantine, H. A., & Anderson, J. M. (2019). Topic choice contributes to the lower rate of NIH awards to African-American/black scientists. *Science Advances*, 5(10), eaaw7238.
- Iwata, R., Kuramoto, K., & Kumagai, S. (2021). Extracting Potential Innovators Using Innovator Scores and Naive Bayes Classifier. 2021 IEEE 10th Global Conference on Consumer Electronics (GCCE),
- Kastrinos, N., & Weber, K. M. (2020). Sustainable development goals in the research and innovation policy of the European Union. *Technological Forecasting and Social Change*, *157*, 120056.
- Kim, J., & Yoo, J. (2019). Science and technology policy research in the EU: from Framework Programme to HORIZON 2020. *Social Sciences*, 8(5), 153.
- Kim, Y. H., Levine, A. D., Nehl, E. J., & Walsh, J. P. (2020). A bibliometric measure of translational science. *Scientometrics*, 125(3), 2349-2382. <u>https://doi.org/10.1007/s11192-020-03668-2</u>
- Laverty, H., & Meulien, P. (2019). The Innovative Medicines Initiative– 10 years of public-private collaboration. *Frontiers in Medicine*, *6*, 275.
- Lawler, M., De Lorenzo, F., Lagergren, P., Mennini, F. S., Narbutas, S., Scocca, G., Meunier, F., & European Academy of Cancer, S. (2021). Challenges and solutions to embed cancer survivorship research and innovation within the EU Cancer Mission. *Molecular Oncology*, 15(7), 1750-1758. <u>https://doi.org/10.1002/1878-0261.13022</u>

- Lewandowska, M. S. (2022). Meeting Grand Challenges: Assessment of Horizon 2020 Health, Demographic Change and Wellbeing Projects. In *Economics and Mathematical Modeling in Health-Related Research* (pp. 121-145). Brill.
- Llewellyn, N., Carter, D. R., DiazGranados, D., Pelfrey, C., Rollins, L., & Nehl, E. J. (2020). Scope, influence, and interdisciplinary collaboration: the publication portfolio of the NIH Clinical and Translational Science Awards (CTSA) Program from 2006 through 2017. *Evaluation and the Health Professions*, *43*(3), 169-179.
- Ludwig, D., Blok, V., Garnier, M., Macnaghten, P., & Pols, A. (2022). What's wrong with global challenges? *Journal of Responsible Innovation*, *9*(1), 6-27.
- Lund, B. D., & Wang, T. (2023). Chatting about ChatGPT: how may AI and GPT impact academia and libraries? *Library Hi Tech News*.
- Lynch, H. F., Morris, S., & Andrews, J. A. (2022). Access to investigational drugs for patients with amyotrophic lateral sclerosis in the USA. *Lancet Neurology*, *21*(7), 593-594.
- Madsen, E. B., & Aagaard, K. (2020). Concentration of Danish research funding on individual researchers and research topics: Patterns and potential drivers. *Quantitative Science Studies*, 1(3), 1159-1181. <u>https://doi.org/10.1162/qss_a_00077</u>
- Mazzucato, M. (2018). *Mission-oriented research & innovation in the European Union : a problemsolving approach to fuel innovation-led growth*. Publications Office. <u>https://doi.org/doi/10.2777/360325</u>
- Mervis, J. (2023). Biden backs science in 2024 spending blueprint. *Science*, *379*(6637), 1078. https://doi.org/10.1126/science.adh8293
- Miller, K., McAdam, R., & McAdam, M. (2018). A systematic literature review of university technology transfer from a quadruple helix perspective: toward a research agenda. *R&D Management*, 48(1), 7-24. <u>https://doi.org/https://doi.org/10.1111/radm.12228</u>
- Morciano, C., Errico, M. C., Faralli, C., & Minghetti, L. (2020). An analysis of the strategic plan development processes of major public organisations funding health research in nine highincome countries worldwide. *Health Research Policy and Systems*, *18*(1), 106. <u>https://doi.org/10.1186/s12961-020-00620-x</u>
- Mugabushaka, A.-M., van Eck, N. J., & Waltman, L. (2022). Funding COVID-19 research: Insights from an exploratory analysis using open data infrastructures. *Quantitative Science Studies*, *3*(3), 560-582. <u>https://doi.org/10.1162/qss_a_00212</u>
- Nathan, D. G., Fontanarosa, P. B., & Wilson, J. D. (2001). Opportunities for medical research in the 21st century. *JAMA*, *285*(5), 533-534.
- National Academies of Sciences, E., & Medicine. (2017). Evaluation of the congressionally directed medical research programs review process.
- National Cancer Institute. (2019). *Strategic Planning at NCI*. <u>https://www.cancer.gov/about-nci/overview/strategic-planning</u>
- National Cancer Institute. (2023). Annual Plan & Budget Proposal for Fiscal Year 2024 At a Glance. Retrieved from <u>https://www.cancer.gov/research/annual-plan/2024-annual-plan-budget-proposal-aag.pdf</u>
- National Heart Lung and Blood Institute. (2016). *Charting the Future Together the NHLBI Strategic Vision*. Retrieved from <u>https://www.nhlbi.nih.gov/sites/default/files/2017-11/NHLBI-Strategic-Vision-2016_FF.pdf</u>
- National Institute of Diabetes and Digestive and Kidney Diseases. (2021). *NIDDK Strategic Plan for Research*. Retrieved from <u>https://www.niddk.nih.gov/-/media/Files/Strategic-Plans/NIDDK-StrategicPlan-2021_508.pdf</u>
- National Institutes of Health. (2015). *NIH-Wide Strategic Plan, Fiscal Years 2016–2020: Turning Discovery Into Health*. Retrieved from <u>https://www.nih.gov/sites/default/files/about-nih/strategic-plan-fy2016-2020-508.pdf</u>
- National Institutes of Health. (2017). *Mission and Goals*. <u>https://www.nih.gov/about-nih/what-we-do/mission-goals</u>

- National Institutes of Health. (2019). NIH strategic plan for HIV and HIV-related research. In: Office of AIDS Research, US Department of Health and Human Services Bethesda.
- National Institutes of Health. (2020a). 2020–2030 Strategic plan for NIH nutrition research: a report of the NIH Nutrition Research Task Force. Retrieved from

https://dpcpsi.nih.gov/sites/default/files/2020NutritionStrategicPlan_508.pdf

- National Institutes of Health. (2020b). NIH-Wide Strategic Plan for Fiscal Years 2021–2025. https://www.nih.gov/sites/default/files/about-nih/strategic-plan-fy2021-2025-508.pdf
- National Institutes of Health. (2021). Minority Health and Health Disparities Strategic Plan 2021– 2025. National Institutes of Health: Bethesda, MD, USA. https://www.nimhd.nih.gov/docs/nimhd-strategic-plan-2021-2025.pdf
- Nederbragt, H. (2000). The biomedical disciplines and the structure of biomedical and clinical knowledge. *Theoretical Medicine and Bioethics*, *21*, 553-566.
- Neta, G., Sanchez, M. A., Chambers, D. A., Phillips, S. M., Leyva, B., Cynkin, L., Farrell, M. M., Heurtin-Roberts, S., & Vinson, C. (2015). Implementation science in cancer prevention and control: a decade of grant funding by the National Cancer Institute and future directions. *Implementation Science*, 10, 1-10.
- Nicholls, M. (2018). Funding of cardiovascular research in the USA: Robert Califf and Peter Libby speak about cardiovascular research funding in the United States and what the latest trends are with Mark Nicholls. *European Heart Journal*, *39*(40), 3629-3631. https://doi.org/10.1093/eurheartj/ehy638
- OECD. (2021). OECD Science, Technology and Innovation Outlook 2021. https://doi.org/doi:https://doi.org/10.1787/75f79015-en
- Palca, J. (1992). NIH Strategic Plan Nears Its Final Form. *Science*, *257*(5069), 476-477. <u>https://doi.org/doi:10.1126/science.1636080</u>
- Pratt, B., Wild, V., Barasa, E., Kamuya, D., Gilson, L., Hendl, T., & Molyneux, S. (2020). Justice: a key consideration in health policy and systems research ethics. *Bmj Global Health*, *5*(4), e001942.
- Rafols, I., Yegros, A., van de Klippe, W., & Willemse, T. (2022). Mapping Research on Cardio-Metabolic Diseases. *SocArXiv*. <u>https://doi.org/10.31235/osf.io/zn5gf</u>
- Reed, J. C., White, E. L., Aubé, J., Lindsley, C., Li, M., Sklar, L., & Schreiber, S. (2012). The NIH's role in accelerating translational sciences. *Nature Biotechnology*, *30*(1), 16-19.
- Renda, A., Del Giovane, C., Iacob, N., & Vu, H. (2023). *Improving the mission, governance and operations of the EU HERA*. CEPS Retrieved from https://cdn.ceps.eu/wp-content/uploads/2023/01/CEPS-In-depth-analysis-2023-01_Mission-governance-and-operations-of-the-EU-HERA.pdf
- Roberts, M. C., Clyne, M., Kennedy, A. E., Chambers, D. A., & Khoury, M. J. (2019). The current state of funded NIH grants in implementation science in genomic medicine: a portfolio analysis. *Genetics in Medicine*, *21*(5), 1218-1223.
- Rodríguez, H., Fisher, E., & Schuurbiers, D. (2013). Integrating science and society in European Framework Programmes: Trends in project-level solicitations. *Research Policy*, *42*(5), 1126-1137.
- Ross, M. B., Glennon, B. M., Murciano-Goroff, R., Berkes, E. G., Weinberg, B. A., & Lane, J. I. (2022). Women are credited less in science than men. *Nature*, *608*(7921), 135-145. <u>https://doi.org/10.1038/s41586-022-04966-w</u>
- Shaw, J. (2022). There and back again: Revisiting Vannevar Bush, the linear model, and the freedom of science. *Research Policy*, *51*(10), 104610.
- Singer, D. S. (2022). A new phase of the Cancer Moonshot to end cancer as we know it. *Nature Medicine*, *28*(7), 1345-1347. <u>https://doi.org/10.1038/s41591-022-01881-5</u>
- Sipido, K., Fajardo, D., Vercruysse, T., Glänzel, W., & Veugelers, R. (2022). *Fostering coherence in EU health research: Strengthening EU research for better health* (978-92-846-9805-9).
- Thorp, H. H. (2022). Will ARPA-H work? *Science*, *376*(6590), 223-223. https://doi.org/10.1126/science.abq4814

- van de Klippe, W., Yegros, A., Willemse, T., & Rafols, I. (2022). Priorities in research portfolios: why more upstream research is needed in cardiometabolic and mental health. *SocArXiv*. <u>https://doi.org/10.31235/osf.io/xrhgd</u>
- Viergever, R. F., & Hendriks, T. C. (2016). The 10 largest public and philanthropic funders of health research in the world: what they fund and how they distribute their funds. *Health Research Policy and Systems*, 14(1), 1-15.
- Wang, S., Scells, H., Koopman, B., & Zuccon, G. (2023). Can chatgpt write a good boolean query for systematic review literature search? *arXiv preprint arXiv:2302.03495*.

Supplementary Material 2 – Validation of KH coder for mapping of terms in health research

Comparison of different community detection methods in the co-occurrence networks of ERC, FP, P01, U01 for the periods 2008-2014 and 2015-2021

In order to determine if the community detection method used by KH Coder could affect the interpretation of co-occurrence networks regarding the content of the projects financed, all the co-occurrence networks generated were analyzed by the community detection methods Leiden, Louvain, 'leading eigenvector' and 'edge betweenness communities'. Taking as an example the case of the co-occurrence network of terms from research projects financed by FP7-health, we see a high degree of overlap between the clusters identified by the different methods used, all of which identify clusters related to the levels biomedical, clinical and health policy research (Figure SM2.1, below).


We further examined more quantitatively the outcomes using different community detection methods, calculating the values of normalized mutual information (NMI) and the RAND index (RAND) to measure the overlap or similarity between two cluster solutions. We found a high degree of correspondence between the different algorithms applied to the data across all funding mechanisms studies (See table below). This implies that the structure detection algorithm used is not a factor that could affect the interpretation of the term co-occurrence networks generated by KH Coder. It is important, however, to keep in mind that the co-occurrence networks are an exploratory tool that allows informing the formulation of a hypothesis about the structure of the content of the projects financed through the different programs analyzed in the present investigation.

	2000-2014	2015-2021
U01	Edge and Leading	Edge and Leading
	NMI = 0.867	NMI = 0.990
	RAND = 0.949	RAND = 0.996
	Leading and Louvain	Leading and Louvain
	NMI = 0.862	NMI = 0.988
	RAND = 0.943	RAND = 0.993
	Louvain and Leiden	Louvain and Leiden
	NMI = 0.963	NMI = 1
	RAND = 0.987	RAND = 1
P01	Edge and Leading	Edge and Leading
	NMI = 0.959	NMI = 0.884
	RAND = 0.977	RAND = 0.911
	Leading and Louvain	Leading and Louvain
	NMI = 0.964	NMI = 0.97
	RAND = 0.977	RAND = 0.979
	Louvain and Leiden	Louvain and Leiden
	NMI = 1	NMI = 1
	RAND = 1	RAND = 1
Framework Programmes	Edge and Leading	Edge and Leading
	NMI = 0.522	NMI = 0.661
	RAND = 0.648	RAND = 0.798
	Leading and Louvain	Leading and Louvain
	NMI = 0.63	NMI = 0.754
	RAND = 0.808	RAND = 0.844
	Louvain and Leiden	Louvain and Leiden
	NMI = 0.634	NMI = 1
	RAND = 0.799	RAND = 1
ERC	Edge and Leading	Edge and Leading
	NMI = 0.895	NMI = 0.708
		RAND = 0.823
	RAND = 0.933	RAND = 0.023
	Leading and Louvain	Leading and Louvain
	Leading and Louvain NMI = 0.903	Leading and Louvain NMI = 0.796
	Leading and Louvain	Leading and Louvain
	Leading and Louvain NMI = 0.903 RAND = 0.918	Leading and Louvain NMI = 0.796 RAND = 0.875
	Leading and Louvain NMI = 0.903	Leading and Louvain NMI = 0.796


Table SM2. Overlapping of structure detection algorithm through normalized mutual information(NMI) and RAND index (RAND)

Figure SM2.1. Co-occurrence network for FP7 using different community detection methods


FP7-health term co-occurrence network with community structure identified using Clauset-Newman modularity in KH Coder




FP7-health term co-occurrence network with community structure identified using the Louvain algorithm




FP7-health term co-occurrence network with community structure identified using the Leiden algorithm



FP7-health term co-occurrence network with community structure identified using the Leading Eigenvector algorithm



FP7-health term co-occurrence network with community structure identified using the Edge Betweenness algorithm



Supplementary Material 3. Funding for health research through R35 and R37 of the NIH

To complement our comparative analysis, we examined funding schemes within NIH that would compare to the ERC granting scheme, i.e. being directed by a single researcher in which the intellectual merit of the project and/or the researcher's trajectory are the fundamental allocation criteria and not the strategic objectives of the funding organization. We chose for analysis two funding streams within NIH that reward outstanding investigators: the Method to Extend Research in Time (MERIT)(R37) and the Maximizing Investigators' Research Award (MIRA) (R35) whose purpose is to provide stability and flexibility to researchers. The difference between both programes is in the operation by different NIH Institutes and in the extent of funding awarded. An investigator who already has project funding under the competitive R01 scheme and who has competencies and performances above his/her peers may be eligible to convert the R01 into an R37 project which gives up to 7 years of funding (initial 5 plus a 2 renewal). A researcher with an exceptional record of academic productivity can apply for an R35 that will give up to ten years of funding, though the implementation varies across NIH institutes. The figure below shows how R35 is a comparatively recent and constantly growing funding stream similar to UM1, while funding through R37 has been on a slight decline over the years.




Figure SM3.1. Annual amount of funding for the NIH P01, R35, R37 UM1 and U01 programs

Regarding the content of the projects of these financing programs, the map of co-occurrence networks of R35 shows how this path is strongly linked to basic biomedical research, particularly research on biomolecular and cellular processes (Figure SM3.2).




Figure SM3.2. Map of co-occurrence of highly frequent terms in the description of projects financed via NIH-R35.

The co-occurrence map of R37, like R35, is strongly oriented towards basic biomedical research, although in the case of R37, subnetworks of clinical terms related to infectious diseases, cancer and alcohol consumption are observed (Figure SM3.3).




Figure SM3.3. Map of co-occurrence of highly frequent terms in the description of projects financed via NIH-R37. (periods 2008-2014, left and 2015-2021, right).

When R35 and R37 are included in the analysis of the distribution of terms coded by research levels (basic, therapeutic, diagnostic, population-based, and health policy), both funding channels are grouped together with the ERC-LS and PO1 given their oriented profile. to basic biomedical research (Figure 4B). There are, however, subtle differences between the R35 and R37. R35 and the 2008-2014 period of R37 are subgrouped together with the ERC-LS, given the scarce presence of non-basic terms among their financed projects (Figure 4B). while the period 2015-2021 of R37 forms a subcluster with PO1 given its relatively higher frequency of therapeutic, diagnostic and population terms.




Figure SM3.4. Heat map and clustering of funding programs according to codified domains of health for research projects in NIH-U01, NIH-P01, NIH-R35, NIH-R37 NIH-UM1, ERC-LS, FP7-health and H2020-health.

The analysis of the distribution of projects classified by research levels among the different funding channels shows that R35 and R37 are very similar to ERC-LS with around 80 percent of their projects being classified as basic biomedical research, followed by the population research and risk factors with just under 10 percent of the projects classified in that category (Figure 5B).




Figure SM3.5. Percentage distribution of projects classified through machine learning by health research levels in NIH-U01, NIH-P01, NIH-R35, NIH-R37 NIH-UM1, ERC-LS, FP7-health and H2020-health